OOIR: Observatory of International Research

Papers

(The median citation count of Health Economics Policy and Law is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
HEP volume 17 issue 4 Cover and Back matter	17
The contaminated blood scandal in England: exploring the social harms experienced by infected and affected individuals	16
Fellow travellers in transformative times: a reflection on 21 years membership of the European Health Policy Group	14
Priority setting for health equality – searching for an ethical framework	12
Reimbursement prices of new, innovative medicines in Germany: a comparison of negotiation and cost-effectiveness analysis	12
Genomics and insurance in the United Kingdom: increasing complexity and emerging challenges	10
New governance of the digital health agency: a way out of the joint decision trap to implement electronic health records in Germany?	9
Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals	9
From speculative to real: community attitudes towards government COVID-19 vaccine mandates in Western Australia from May 2021 to April 2022	8
Institutional boundaries and the challenges of aligning science advice and policy dynamics: the UK and Canada in the time of COVID-19	7
Out with the old…	7
Judicial claims for access to treatment in the private health insurance sector in Brazil	7
HEP volume 17 issue 2 Cover and Front matter	7
Saving children's lives through interventions: a quasi-experimental analysis of GAVI	6
Managed competition in Colombia: convergence of public and private insurance and delivery	6
Politics in all policies: how healthcare is shaped by political (in)action	6
Preconditions for efficiency and affordability in mixed health systems: are they fulfilled in the Australian public–private mix?	5
A review of heath economic evaluation practice in the Netherlands: are we moving forward?	5
Neighborhood inequalities and the decline of infant mortality in São Paulo	4
The state of American health coverage: the 2022 elections and the Affordable Care Act	4
Making care primary: a renewed investment into primary care	4
Exploring differences between public and private providers in primary care: findings from a large Swedish region	4
Value-based evidence across health care sectors: a push for transparent real-world studies, data, and evidence dissemination	4
Fair processes for financing universal health coverage?	4
Financial risk protection in private health insurance: empirical evidence on catastrophic and impoverishing spending from Germany's dual insurance system	4

Healthcare reform in the Netherlands: after 15 years of regulated competition	4
An examination of health care efficiency in Canada: a two-stage semi-parametric approach	4
The roads to managed competition for mixed public–private health systems: a conceptual framework	3
Navigating conflicting expectations in addressing healthcare scarcity: a q-methodology study on the Dutch National Health Care Institute	3
… and in with the new	3
Medical marijuana laws and mental health in the United States	3
Primary care as determinant of COVID-19 and influenza vaccine uptake	3
Do consumers perceive and trust health insurers within a system of managed competition as prudent buyers of care?	3
Political determinants of health: (re) examining the role of governance in reducing maternal mortality	3
Promoting the systematic use of real-world data and real-world evidence for digital health technologies across Europe: a consensus framework	3
HEP volume 17 issue 1 Cover and Front matter	3
Has regional decentralisation saved lives during the COVID-19 pandemic?	3
Privatising, liberalising and dividing a welfare state without affecting universality? Debunking the myths surrounding the rapid rise of private health insurance in Sweden	3
Why procedural fairness is essential to financing universal health coverage	2
Health misinformation and freedom of expression: considerations for policymakers	2
Integrated care in a Beveridge system: experiences from England and Denmark	2
Accelerating integration of social needs into mainstream healthcare to achieve health equity in the COVID-19 era	2
Early child health in Africa: do ICT and democracy matter?	2
Reforming the funding of long-term care for older people: costs and distributional impacts of planned changes in England	2
Private equity involvement in primary care: the case of Ireland	2
Successfully changing the mode of regulation in clinical priority setting: how organisational factors contributed to establishing the Norwegian priority guidelines for specialist health care services	2
Response to critics of Open and Inclusive: Fair Processes for Financing Universal Health Coverage	2
Regulated markets and rationalised myths: an institutional perspective on value-based purchasing in the Netherlands	2
If you were a policymaker, which treatment would you disinvest? A participatory value evaluation on public preferences for active disinvestment of health care interventions in the Netherlands	1
‘Nurses are seen as general cargo, not the smart TVs you ship carefully’: the politics of nurse staffing in England, Spain, Sweden, and the Netherlands	1
Improving access to healthcare in Ireland: an implementation failure	1
The still incomplete pursuit of universal access to medicines	1
Roadmaps to managed competition: to what extent does South Africa meet the preconditions for equity and efficiency?	1
The impact of surprise billing laws on hospital-based physician prices and network participation	1
Pandemic preparedness and response: a new mechanism for expanding access to essential countermeasures	1
Managed competition in Aotearoa New Zealand: past experiences and future prospects	1
A systematic literature review of real-world evidence (RWE) on post-market assessment of medical devices	1
Coping with COVID-19: the role of hospital care structures and capacity expansion in five countries	1
How should medicines reimbursement work? The views of Spanish experts	1
The mixed legacy of managed competition: between policy and practice	1
Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit	1
How reforms hamper priority-setting in health care: an interview study with local decision-makers in London	1
Health system sustainability and resilience: a preliminary provision of measurement through a “mash-up” index	1
Managed competition in the United States: How well is it promoting equity and efficiency?	1